66.81 USD
-0.32
0.48%
Updated Aug 26, 1:36 PM EDT
1 day
-0.48%
5 days
-1.79%
1 month
1.70%
3 months
7.46%
6 months
3.81%
Year to date
-6.87%
1 year
-16.23%
5 years
1.37%
10 years
72.55%
 

About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Employees: 7,063

0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 6 (+3) [Q2]

5% more capital invested

Capital invested by funds: $13.5B [Q1] → $14.2B (+$690M) [Q2]

2% more first-time investments, than exits

New positions opened: 102 | Existing positions closed: 100

0.49% more ownership

Funds ownership: 97.43% [Q1] → 97.92% (+0.49%) [Q2]

2% less funds holding

Funds holding: 692 [Q1] → 676 (-16) [Q2]

17% less repeat investments, than reductions

Existing positions increased: 220 | Existing positions reduced: 266

26% less call options, than puts

Call options by funds: $44.1M | Put options by funds: $59.5M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$68
2%
upside
Avg. target
$74
11%
upside
High target
$87
30%
upside

6 analyst ratings

positive
50%
neutral
50%
negative
0%
RBC Capital
Conor McNamara
30%upside
$87
Outperform
Upgraded
6 Aug 2025
Morgan Stanley
Tejas Savant
3%upside
$69
Equal-Weight
Maintained
31 Jul 2025
UBS
Elizabeth Garcia
5%upside
$70
Neutral
Maintained
31 Jul 2025
Mizuho
Anthony Petrone
5%upside
$70
Outperform
Maintained
16 Jul 2025
Citigroup
Patrick Donnelly
20%upside
$80
Buy
Upgraded
9 Jul 2025

Financial journalist opinion

Based on 19 articles about HOLX published over the past 30 days

Positive
Zacks Investment Research
3 hours ago
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
Positive
Zacks Investment Research
1 day ago
HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow?
Two MedTech giants, one clear winner. Boston Scientific's momentum outpaces Hologic's cautious rise.
HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow?
Positive
Zacks Investment Research
6 days ago
Here's Why Hologic (HOLX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Hologic (HOLX) is a Strong Value Stock
Positive
Zacks Investment Research
6 days ago
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Positive
Zacks Investment Research
1 week ago
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Positive
Zacks Investment Research
1 week ago
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
Positive
Zacks Investment Research
2 weeks ago
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
Positive
Zacks Investment Research
2 weeks ago
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?
HOLX rises post earnings beat, fueled by Diagnostics strength and Surgical growth. However, macro headwinds persist.
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?
Positive
Zacks Investment Research
3 weeks ago
Why Hologic (HOLX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Hologic (HOLX) is a Top Value Stock for the Long-Term
Positive
Zacks Investment Research
3 weeks ago
Interpreting Hologic (HOLX) International Revenue Trends
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Interpreting Hologic (HOLX) International Revenue Trends
Charts implemented using Lightweight Charts™